Fenebrutinib (GDC-0853)


For research use only.

Fenebrutinib (GDC-0853) is a potent, selective, and non-covalent bruton's tyrosine kinase (BTK) inhibitor with an Ki value of 0.91 nM for Btk with >100-fold selectivity over 3 off-targets (Bmx :153-fold, Fgr: 168-fold, Src:131-fold).

Fenebrutinib (GDC-0853)化学構造

CAS No. 1434048-34-6

サイズ 価格(税別)
JPY 23100
JPY 34600

代表番号: 03-5615-9297|電子メール:[email protected]





製品説明 Fenebrutinib (GDC-0853) is a potent, selective, and non-covalent bruton's tyrosine kinase (BTK) inhibitor with an Ki value of 0.91 nM for Btk with >100-fold selectivity over 3 off-targets (Bmx :153-fold, Fgr: 168-fold, Src:131-fold).
BTK [1]
(Cell-free assay)
BTK C481R [1]
(Cell-free assay)
BTK C481S [1]
(Cell-free assay)
BTK T474M [1]
(Cell-free assay)
BTK T474I [1]
(Cell-free assay)
0.91 nM(Ki) 1.3 nM(Ki) 1.6 nM(Ki) 3.4 nM(Ki) 12.6 nM(Ki)

When tested at 1 μM against a broad panel of human kinase biochemical assays, GDC-0853 inhibits only 3 of 286 off-target kinases. Based on the determined IC50 values, the selectivity for Btk is >100-fold against each of these 3 off-targets: Bmx (153-fold), Fgr (168-fold), and Src (131-fold). GDC-0853 blocks both B-cell BCR and monocyte FcγR signaling. In in vitro biochemical Btk enzyme assay, GDC-0853 displays an average residence time with Btk of 18.3 ± 2.8 hours. GDC-0853 blocks cellular autophosphorylation of WT Btk and the C481S mutant[1]. CLL (chronic lymphocytic leukemia) cells treated with GDC-0853 in vitro before BCR stimulation demonstrate reduced levels of BTK phosphorylation and diminished activation of downstream targets including PLCγ2, AKT, and ERK. GDC-0853 inhibits NF-κB–dependent transcription, reduces activation, and impairs migration. GDC-0853 lacks inhibition of EGFR and ITK in cellular system and does not affect T-cell receptor activation[3].

Methods Test Index PMID
Western blot p-BTK / BTK / p-PLCγ2 / PLCγ2 / p-AKT / AKT / p-ERK / ERK 30018078

In rats administrated 0.2 mg/kg GDC-0853 via intraperitoneal injection or 1 mg/kg PO, GDC-0853 has moderate clearance of 27.4 mL/min/kg and excellent bioavailability (F=65%). The plasma clearance is 27.4 mL/min/kg, the volume of distribution (Vd) is 5.42 L/kg and the plasma half-life (t1/2) is 2.2 h. GDC-0853 also demonstrates favorable PK properties in dogs. The 3.8-hour half-life (Clp 10.9 mL/min/kg, Vd 2.96 L/kg) and high oral bioavailability (85%) also enable attainment of sufficient exposures in dog toxicology studies. GDC-0853 is well tolerated in both rats and dogs and displays an overall favorable safety profile. GDC-0853 is useful in treating rheumatoid arthritis and other B-cell or myeloid cell mediated autoimmune diseases. In a single ascending dose (SAD) study (0.5 mg to 600 mg) and multiple ascending dose (MAD) study for 14 days (250 mg BID to 500 mg QD), GDC-0853 is very well tolerated with no severe adverse events, no safety signals, and no dose limiting toxicities. GDC-0853 is well absorbed and had linear, doseproportional pharmacokinetics[1]. In Sprague-Dawley (SD) rats, administration of GDC-0853 and other structurally diverse BTK inhibitors for 7 days or longer cause pancreatic lesions consisting of multifocal islet-centered hemorrhage, inflammation, fibrosis, and pigment-laden macrophages with adjacent lobular exocrine acinar cell atrophy, degeneration, and inflammation. Similar findings are not observed in mice or dogs at much higher exposures[2].




  • Kinase selectivity:

    Btk inhibitor kinase selectivity is assessed at a concentration of 1 µM in a panel of up to 287 recombinant human kinase activity and binding assays, including cytoplasmic and receptor tyrosine kinases, serine/threonine kinases, and lipid kinases. The kinase activity assays measure peptide phosphorylation or ADP production while the binding assays monitored displacement of ATP sitebinding probes. The ATP concentrations used in the activity assays are typically within 2-fold of the experimentally determined apparent Michaelis constant (Kmapp) value for each kinase while the competitive binding tracer concentrations used in the binding assays are generally within 3-fold of the experimentally determined dissociation constant (Kd) values. Inhibitors are tested in duplicate against each kinase and the mean % Inhibition values are reported. For kinases that are inhibited by close to or greater than 80% at the test concentration, 10-point inhibitor titrations using the same assays are carried out in order to determine the inhibitor concentrations that caused 50% inhibition (IC50).



  • 細胞株:CLL cells
  • 濃度: 1 μM
  • 反応時間:48 hours
  • 実験の流れ:

    Cells are treated with 1 µM BTK inhibitor for 48 hours and measured for viability by flow cytometry.



  • 動物モデル:Sprague-Dawley, Wistar-Han and Fischer-344 rats (6 to 12 weeks old)
  • 投薬量:5 or 10 mL/kg
  • 投与方法:p.o.

溶解度 (25°C)



分子量 664.80


CAS No. 1434048-34-6
Storage 3年 -20°C
2年 -80°C in solvent
Smiles CC1CN(CCN1C2=CN=C(C=C2)NC3=CC(=CN(C3=O)C)C4=C(C(=NC=C4)N5CCN6C7=C(CC(C7)(C)C)C=C6C5=O)CO)C8COC8



mg/kg g μL


% DMSO % % Tween 80 % ddH2O


投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。



質量 濃度 体積 分子量


NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05119569 Recruiting Drug: fenebrutinib|Drug: placebo Relapsing Multiple Sclerosis Hoffmann-La Roche March 1 2022 Phase 2
NCT04586023 Recruiting Drug: fenebrutinib|Drug: teriflunomide|Drug: placebo Relapsing Multiple Sclerosis Hoffmann-La Roche March 24 2021 Phase 3
NCT04586010 Recruiting Drug: fenebrutinib|Drug: teriflunomide|Drug: placebo Relapsing Multiple Sclerosis Hoffmann-La Roche March 17 2021 Phase 3
NCT04544449 Recruiting Drug: fenebrutinib|Drug: ocrelizumab|Drug: placebo Multiple Sclerosis Primary Progressive Hoffmann-La Roche October 26 2020 Phase 3
NCT03693625 Terminated Drug: GDC-0853 Urticaria Genentech Inc. September 27 2018 Phase 2
NCT03596632 Completed Drug: Fenebrutinib Healthy Participants Hoffmann-La Roche July 27 2018 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)



Handling Instructions


* 必須

電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
Tags: Fenebrutinib (GDC-0853)を買う | Fenebrutinib (GDC-0853) ic50 | Fenebrutinib (GDC-0853)供給者 | Fenebrutinib (GDC-0853)を購入する | Fenebrutinib (GDC-0853)費用 | Fenebrutinib (GDC-0853)生産者 | オーダーFenebrutinib (GDC-0853) | Fenebrutinib (GDC-0853)化学構造 | Fenebrutinib (GDC-0853)分子量 | Fenebrutinib (GDC-0853)代理店